KPRX News and Press, Kiora Pharmaceuticals Inc. From 06/02/23

2023-06-02 09:32:21 ET Kiora Pharmaceuticals ( NASDAQ: KPRX ) stock dropped 50% on Friday after the firm priced an underwritten public offering for gross proceeds of ~$5.5M. The offering is comprised of ~1.4M shares, 3.9K series F convertible preferred shares, 5M class...

Encinitas, California--(Newsfile Corp. - June 2, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the pricing of an underwritten public offering for gross proceeds of approximately $5.5 million prior to deducting underwriting discounts and commissions ...

2023-06-02 08:11:37 ET SentinelOne ( S ) -36% after Q1 results . Kiora Pharmaceuticals ( KPRX ) -36% . Tigo Energy ( TYGO ) -16% . PagerDuty ( PD ) -16% . after Q1 results . Immutep ( IMMP ) -10% . Harbor Custom Developme...

2023-05-09 08:45:15 ET Kiora Pharmaceuticals press release ( NASDAQ: KPRX ): Q1 Net loss was $1.9 million for the first quarter of 2023 compared to $3.6 million for the first quarter of 2022. Kiora ended the quarter with $3.4 million in cash and cash equivalents as well as...

Encinitas, California--(Newsfile Corp. - May 9, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) announced its first quarter 2023 results, during which time it significantly advanced its ocular drug development pipeline of clinical-stage candidates for the treatment of Retinitis Pigmentosa (RP), Pers...

Encinitas, California--(Newsfile Corp. - May 1, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) announced today an encore presentation on KIO-301 neuroimaging results at The American Society of Neuroradiology 2023 Meeting in Chicago. The late-breaking abstract presentation titled "Functional Visio...

Encinitas, California--(Newsfile Corp. - April 27, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) presented preliminary results from an ongoing clinical trial showing its investigational drug, KIO-301, has the potential to restore light perception in patients who are blind or living with ultra-...

In a second presentation, Kiora shared additional positive results for its KIO-100 platform in the treatment of autoimmune uveitis. Encinitas, California--(Newsfile Corp. - April 26, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) presented results of a Phase 2 clinical trial for KIO-201 treating p...

2023-04-24 10:08:54 ET Gainers: IN8bio ( INAB ) +121% . IDEAYA Biosciences ( IDYA ) +27% . ZyVersa Therapeutics ( ZVSA ) +26% .  Koninklijke Philips ( PHG ) +15% . Kiora Pharmaceuticals ( KPRX ) +9% . Losers: Scilex H...

Encinitas, California--(Newsfile Corp. - April 21, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed Mark Pennesi, M.D., Ph.D., the Kenneth C. Swan Endowed Professor in Ophthalmology and Molecular and Medical Genetics and the Chief of the Paul H. Casey Ophthalmic Genetics Division at the...